Phillip Simmons

501 total citations
18 papers, 344 citations indexed

About

Phillip Simmons is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Phillip Simmons has authored 18 papers receiving a total of 344 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Surgery, 7 papers in Pulmonary and Respiratory Medicine and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Phillip Simmons's work include Lipoproteins and Cardiovascular Health (6 papers), Neonatal Respiratory Health Research (5 papers) and Heart Failure Treatment and Management (4 papers). Phillip Simmons is often cited by papers focused on Lipoproteins and Cardiovascular Health (6 papers), Neonatal Respiratory Health Research (5 papers) and Heart Failure Treatment and Management (4 papers). Phillip Simmons collaborates with scholars based in United States, Poland and Greece. Phillip Simmons's co-authors include John R. Guyton, Mark E. McGovern, Harold Bays, Peter O. Kwiterovich, Boris Kerzner, Kathleen Berra, Phillip D. Toth, Wayne L. Harper, Stephen D. Nash and Moti L. Kashyap and has published in prestigious journals such as Journal of the American College of Cardiology, Cancer Research and The American Journal of Cardiology.

In The Last Decade

Phillip Simmons

17 papers receiving 326 citations

Peers

Countries citing papers authored by Phillip Simmons

Since Specialization

Citations

This map shows the geographic impact of Phillip Simmons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phillip Simmons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phillip Simmons more than expected).

Fields of papers citing papers by Phillip Simmons

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phillip Simmons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phillip Simmons. The network helps show where Phillip Simmons may publish in the future.

Co-authorship network of co-authors of Phillip Simmons

This figure shows the co-authorship network connecting the top 25 collaborators of Phillip Simmons. A scholar is included among the top collaborators of Phillip Simmons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phillip Simmons. Phillip Simmons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Safety and efficacy intravenous istaroxime up to 60 hours for patients with pre-cardiogenic shock 2025 ·The Journal of Heart and Lung Transplantation ·Jan Biegus, Alexandre Mebazaa, Marco Metra, Matteo Pagnesi, Ovidiu Chioncel, (unknown), Christopher Edwards, Koji Takagi, (unknown), Agnieszka Tycińska, Maria Novosadova, Gaurav Gulati, Marianela Barros, (unknown), (unknown), Robert Zymliński, Piotr Gajewski, Piotr Ponikowski, Phillip Simmons, Steven G. Simonson, Gad Cotter	1
2	Safety and Efficacy of up to 60 h of iv Istaroxime in Pre-Cardiogenic Shock Patients: Design of the SEISMiC Trial 2024 ·ESC Heart Failure ·Jan Biegus, Alexander Mebazaa, Marco Metra, Matteo Pagnesi, Ovidiu Chioncel, (unknown), (unknown), Agnieszka Tycińska, Maria Novosadova, Gaurav Gulati, Marianela Barros, (unknown), (unknown), Robert Zymliński, Piotr Gajewski, Piotr Ponikowski, Phillip Simmons, Steven G. Simonson, Gad Cotter	4
3	Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients With Pre-Cardiogenic Shock 2023 ·Journal of Cardiac Failure ·Marco Metra, Ovidiu Chioncel, Beth A. Davison, Gerasimos Filippatos, Alexandre Mebazaa, Matteo Pagnesi, Marianna Adamo, Maria Novosadova, Piotr Ponikowski, Phillip Simmons, (unknown), Steven G. Simonson, Gad Cotter	5
4	Safety and efficacy of istaroxime in patients with acute heart failure‐related pre‐cardiogenic shock – a multicentre, randomized, double‐blind, placebo‐controlled, parallel group study ( SEISMiC ) 2022 ·European Journal of Heart Failure ·Marco Metra, Ovidiu Chioncel, Gad Cotter, Beth A. Davison, Gerasimos Filippatos, Alexandre Mebazaa, Maria Novosadova, Piotr Ponikowski, Phillip Simmons, (unknown), Steven G. Simonson	26
5	Treatment with 24 Hour Istaroxime Infusion in Patients Hospitalised for Acute Heart Failure: A Randomised, Placebo-Controlled Trial 2020 ·European Journal of Heart Failure ·Valentina Carubelli, Yuhui Zhang, Marco Metra, Carlo Lombardi, G. Michael Felker, Gerasimos Filippatos, Christopher M. O’Connor, John R. Teerlink, Phillip Simmons, Robert Segal, Gabriella Malfatto, Maria Teresa La Rovere, Dianfu Li, Xiumin Han, Zuyi Yuan, (unknown), Benjamin Li, (unknown), Giuseppe Bianchi, Jian Zhang, (unknown)	42
6	Prospective observational study of early respiratory management in preterm neonates less than 35 weeks of gestation 2019 ·BMC Pediatrics ·(unknown), Fernando Moya, Jan Mazela, Paul Shore, Steven G. Simonson, Robert Segal, Phillip Simmons, (unknown), (unknown), (unknown), Neil N. Finer	19
7	Parental preferences regarding administration of an animal-derived versus a synthetic medication to newborn infants 2016 ·Journal of Neonatal-Perinatal Medicine ·(unknown), Fernando Moya, Phillip Simmons, (unknown), Thomas H. Shaffer	2
8	Fabulous fluorites and other minerals from Cooke's Peak: following in the footsteps of a legend 2016 ·(unknown), Phillip Simmons	1
9	A pilot, randomized, controlled clinical trial of lucinactant, a peptide-containing synthetic surfactant, in infants with acute hypoxemic respiratory failure 2012 ·Pediatric Critical Care Medicine ·Neal J. Thomas, (unknown), Fernando Moya, Ira M. Cheifetz, Barry P. Markovitz, Pablo Cruces, (unknown), Robert Segal, Phillip Simmons, Adrienne G. Randolph	20
10	Abstract PD07-09: Zoledronate versus ibandronate comparative evaluation (ZICE) trial - first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases. 2012 ·Cancer Research ·Peter Barrett‐Lee, Angela Casbard, Jame Abraham, Richard Grieve, Duncan Wheatley, Phillip Simmons, RE Coleman, Kerenza Hood, Gareth Griffiths, Nicholas Murray	4
11	A Pharmacoeconomic Analysis of In-Hospital Costs Resulting from Reintubation in Preterm Infants Treated with Lucinactant, Beractant, or Poractant Alfa 2012 ·The Journal of Pediatric Pharmacology and Therapeutics ·(unknown), Fernando Moya, Sunil K. Sinha, Phillip Simmons, Robert Segal, Jay S. Greenspan	7
12	Reintubation and risk of morbidity and mortality in preterm infants after surfactant replacement therapy 2011 ·Journal of Neonatal-Perinatal Medicine ·(unknown), Fernando Moya, Sunil K. Sinha, Janusz Gadzinowski, Steven M. Donn, Phillip Simmons, Robert Segal	9
13	Flushing and other dermatologic adverse events associated with extended-release niacin therapy 2009 ·Journal of clinical lipidology ·John R. Guyton, Phillip Simmons	8
14	820-5 Once-daily niacin extended-release/lovastatin combination is effective and safe for treatment of dyslipidemia associated with metabolic syndrome 2004 ·Journal of the American College of Cardiology ·Mark E. McGovern, (unknown), Phillip Simmons, Eric J. Stanek	2
15	Safety of combination therapy with once-daily niacin extended-release/lovastatin in over 4,000 patients participating in the impact of medical subspecialty on patient compliance to treatment study 2003 ·Journal of the American College of Cardiology ·Mark E. McGovern, (unknown), (unknown), (unknown), (unknown), Phillip Simmons, William M. Gentry	2
16	Effectiveness of aggressive management of dyslipidemia in a collaborative-care practice model 2003 ·The American Journal of Cardiology ·Michael J. Ryan, (unknown), Phillip Simmons, Eric J. Stanek	8
17	Lipoprotein effects of a new dual component drug (extended-release niacin/lovastatin) compared to starting doses of atorvastatin and simvastatin 2002 ·Journal of the American College of Cardiology ·Harold Bays, Mark E. McGovern, Phillip Simmons	2
18	Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia*A complete list of participants in the Research Group and Publication Committee appears in the Appendix. 2002 ·The American Journal of Cardiology* ·Moti L. Kashyap, Mark E. McGovern, Kathleen Berra, John R. Guyton, Peter O. Kwiterovich, Wayne L. Harper, Phillip D. Toth, (unknown), Boris Kerzner, Stephen D. Nash, Harold Bays, Phillip Simmons	182

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact